Targeting ELTD1, an angiogenesis marker for glioblastoma (GBM), also affects VEGFR2: molecular-targeted MRI assessment.

No abstract is available for this paper.

• Publication year

  2019

• Venue

  American Journal of Nuclear Medicine and Molecular Imaging

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Engineering

• Identifiers
  PMID 30911439PMCID PMC6420708
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic and Therapeutic Biomarkers in Glioblastoma: Current Status and Future Perspectives

  2017influential reference
• CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014

  2017cited by this paper
• Advances in the molecular genetics of gliomas — implications for classification and therapy

  2017cited by this paper
• Silencing of epidermal growth factor, latrophilin and seven transmembrane domain-containing protein 1 (ELTD1) via siRNA-induced cell death in glioblastoma

  2017cited by this paper
• Anti-miR delivery strategies to bypass the blood-brain barrier in glioblastoma therapy

  2016cited by this paper
• Magnetic Resonance Imaging Physical Principles And Sequence Design

  2016cited by this paper
• VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis

  2016cited by this paper
• Autocrine VEGFR1 and VEGFR2 signaling promotes survival in human glioblastoma models in vitro and in vivo

  2016cited by this paper
• The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary

  2016cited by this paper
• ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models

  2016influential reference
• Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy

  2015cited by this paper
• Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date

  2015influential reference
• Molecular Heterogeneity in Glioblastoma: Potential Clinical Implications

  2015cited by this paper
• A review of ELTD1, a pro-angiogenic adhesion GPCR.

  2014cited by this paper
• Heterogeneity of Tumor Vasculature and Antiangiogenic Intervention: Insights from MR Angiography and DCE-MRI

  2014cited by this paper
• Using the molecular classification of glioblastoma to inform personalized treatment

  2014influential reference
• STRING v10: protein–protein interaction networks, integrated over the tree of life

  2014cited by this paper
• Angiogenesis in glioblastoma.

  2013cited by this paper
• A Core Human Primary Tumor Angiogenesis Signature Identifies the Endothelial Orphan Receptor ELTD1 as a Key Regulator of Angiogenesis

  2013influential reference
• Angiopoietin-2 functions as a Tie2 agonist in tumor models, where it limits the effects of VEGF inhibition.

  2013cited by this paper
• ELTD1, a potential new biomarker for gliomas.

  2013influential reference
• Phase II Study of Bevacizumab in Combination with Sorafenib in Recurrent Glioblastoma (N0776): A North Central Cancer Treatment Group Trial

  2013cited by this paper
• Experimental validation of 5 in-silico predicted glioma biomarkers.

  2013cited by this paper
• Emerging insights into the molecular and cellular basis of glioblastoma.

  2012cited by this paper
• Autocrine VEGF–VEGFR2–Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth

  2012cited by this paper
• Transcriptional profiling of human glioblastoma vessels indicates a key role of VEGF‐A and TGFβ2 in vascular abnormalization

  2012cited by this paper
• Continuous daily sunitinib for recurrent glioblastoma

  2012cited by this paper
• VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex.

  2012cited by this paper
• A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma.

  2011cited by this paper
• Angiopoietin 2 Stimulates TIE2-Expressing Monocytes To Suppress T Cell Activation and To Promote Regulatory T Cell Expansion

  2011cited by this paper
• Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme.

  2011cited by this paper
• Predicting gene ontology from a global meta-analysis of 1-color microarray experiments

  2011cited by this paper
• Variation at the NFATC2 Locus Increases the Risk of Thiazolidinedione-Induced Edema in the Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM) Study

  2010cited by this paper
• Clinical relevance of vascular endothelial growth factor (VEGFA) and VEGF receptor (VEGFR2) gene polymorphism on the treatment outcome following imatinib therapy.

  2010cited by this paper
• Effect of CYP3A-inducing anti-epileptics on sorafenib exposure: results of a phase II study of sorafenib plus daily temozolomide in adults with recurrent glioblastoma

  2010cited by this paper
• Direct contacts between extracellular membrane-proximal domains are required for VEGF receptor activation and cell signaling

  2010cited by this paper
• In vivo detection of inducible nitric oxide synthase in rodent gliomas.

  2010cited by this paper
• Multiparametric assessment of the anti‐glioma properties of OKN007 by magnetic resonance imaging

  2010cited by this paper
• Analysis of Germline Variants in CDH1, IGFBP3, MMP1, MMP3, STK15 and VEGF in Familial and Sporadic Renal Cell Carcinoma

  2009cited by this paper
• Allelic variations in angiogenic pathway genes are associated with preeclampsia.

  2009cited by this paper
• Autocrine loop between vascular endothelial growth factor (VEGF)-C and VEGF receptor-3 positively regulates tumor-associated lymphangiogenesis in oral squamoid cancer cells.

  2009cited by this paper
• Angiopoietin 2 Is a Partial Agonist/Antagonist of Tie2 Signaling in the Endothelium

  2009cited by this paper
• Genome-Wide Association Scan Identifies Variants near Matrix Metalloproteinase (MMP) Genes on Chromosome 11q21–22 Strongly Associated With Serum MMP-1 Levels

  2009cited by this paper
• Clinical significance of a single nucleotide polymorphism and allelic imbalance of matrix metalloproteinase-1 promoter region in prostate cancer.

  2009cited by this paper
• Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival.

  2009cited by this paper
• BEVACIZUMAB FOR RECURRENT MALIGNANT GLIOMAS: EFFICACY, TOXICITY, AND PATTERNS OF RECURRENCE

  2009cited by this paper
• Cell-Cell Contact Formation Governs Ca2+ Signaling by TRPC4 in the Vascular Endothelium

  2009cited by this paper
• Gene polymorphisms related to angiogenesis, inflammation and thrombosis that influence risk for oral cancer.

  2009cited by this paper
• Advanced imaging techniques in brain tumors

  2009cited by this paper
• A global meta-analysis of microarray expression data to predict unknown gene functions and estimate the literature-data divide

  2009cited by this paper
• Analysis of the coding regions of VEGFR3 and VEGFC in Milroy disease and other primary lymphoedemas

  2009cited by this paper
• The -271 G>A polymorphism of kinase insert domain-containing receptor gene regulates its transcription level in patients with non-small cell lung cancer

  2009cited by this paper
• VEGF-dependent tumor angiogenesis requires the inverse and reciprocal regulation of VEGFR1 and VEGFR2

  2009cited by this paper
• Recessive primary congenital lymphoedema caused by a VEGFR3 mutation

  2009cited by this paper
• Dinucleotide repeat polymorphism in Fms-like tyrosine kinase-1 (Flt-1) gene is not associated with preeclampsia

  2008cited by this paper
• Novel splice variants derived from the receptor tyrosine kinase superfamily are potential therapeutics for rheumatoid arthritis

  2008cited by this paper
• Title Association between promoter-1607 polymorphism of MMP 1 and lumbar disc disease in Southern Chinese

  2008cited by this paper
• Nuclear FAK promotes cell proliferation and survival through FERM-enhanced p53 degradation.

  2008cited by this paper
• Natural selection of FLT1 alleles and their association with malaria resistance in utero

  2008cited by this paper
• A novel VEGFR3 mutation causes Milroy disease

  2007cited by this paper
• Malignant astrocytic glioma: genetics, biology, and paths to treatment.

  2007cited by this paper
• Binding of Cbl to a phospholipase Cgamma1-docking site on platelet-derived growth factor receptor beta provides a dual mechanism of negative regulation.

  2007cited by this paper
• Activation of FAK is necessary for the osteogenic differentiation of human mesenchymal stem cells on laminin‐5

  2007cited by this paper
• Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments

  2006cited by this paper
• Microtubule-induced focal adhesion disassembly is mediated by dynamin and focal adhesion kinase

  2005cited by this paper
• Direct Interaction of the N-terminal Domain of Focal Adhesion Kinase with the N-terminal Transactivation Domain of p53*

  2005cited by this paper
• Expression and function of vascular endothelial growth factor receptor-1 on human colorectal cancer cells

  2005cited by this paper
• VEGF‐A Angiogenesis Induces a Stable Neovasculature in Adult Murine Brain

  2004cited by this paper
• Shared relationship analysis: ranking set cohesion and commonalities within a literature-derived relationship network

  2004cited by this paper
• Extending the mutual information measure to rank inferred literature relationships

  2004cited by this paper
• Development of hygromas or severe edema during treatment with the tyrosine kinase inhibitor STI571 is not associated with platelet-derived growth factor receptor (PDGFR) gene polymorphisms.

  2004cited by this paper
• Focal Adhesion Kinase Is Upstream of Phosphatidylinositol 3-Kinase/Akt in Regulating Fibroblast Survival in Response to Contraction of Type I Collagen Matrices via a β1 Integrin Viability Signaling Pathway*

  2004cited by this paper
• MRI and fluorescence microscopy of the acute vascular response to VEGF165: vasodilation, hyper‐permeability and lymphatic uptake, followed by rapid inactivation of the growth factor

  2002cited by this paper
• ETL, a Novel Seven-transmembrane Receptor That Is Developmentally Regulated in the Heart

  2001cited by this paper
• Perfusion MR Imaging in Gliomas: Comparison with Histologic Tumor Grade

  2001cited by this paper
• Site-selective Dephosphorylation of the Platelet-derived Growth Factor β-Receptor by the Receptor-like Protein-tyrosine Phosphatase DEP-1*

  2000cited by this paper
• Vascular Endothelial Cadherin (VE‐Cadherin): Cloning and Role in Endothelial Cell‐Cell Adhesion

  1997cited by this paper
• Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution.

  1997cited by this paper
• Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis.

  1997cited by this paper
• Functional properties of human vascular endothelial cadherin (7B4/cadherin-5), an endothelium-specific cadherin.

  1995cited by this paper
• Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor.

  1992cited by this paper
• Chromosomal localization of FLT4, a novel receptor-type tyrosine kinase gene.

  1992cited by this paper
• Diversity of the cadherin family: evidence for eight new cadherins in nervous tissue.

  1991cited by this paper
• Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family.

  1990cited by this paper
• What is the Correct Value for the Brain-Blood Partition Coefficient for Water?

  1985cited by this paper
• Oncotargets and Therapy Dovepress Epidermal Growth Factor, Latrophilin, and Seven Transmembrane Domain-containing Protein 1 Marker, a Novel Angiogenesis Marker

  year unknowncited by this paper

• Structure of the Gq-coupled adhesion receptor ADGRL4

  2025cites this paper
• Clinicopathological Parameters and Immunohistochemical Profiles in Correlation with MRI Characteristics in Glioblastomas

  2024cites this paper
• Multiple therapeutic approaches of glioblastoma multiforme: From terminal to therapy.

  2023cites this paper
• Advances in antibody-based drugs and their delivery through the blood-brain barrier for targeted therapy and immunotherapy of gliomas.

  2023cites this paper
• ELTD1 is present in extracellular vesicles derived from endothelial cells as a cleaved extracellular domain which induces in vivo angiogenesis

  2022cites this paper
• Uncovering a Distinct Gene Signature in Endothelial Cells Associated With Contrast Enhancement in Glioblastoma

  2021cites this paper
• Pre-Clinical Models and Potential Novel Therapies for Glioblastomas

  2021cites this paper
• ELTD1 deletion reduces vascular abnormality and improves T-cell recruitment after PD-1 blockade in glioma

  2021cites this paper
• ADGRL4/ELTD1 Expression in Breast Cancer Cells Induces Vascular Normalization and Immune Suppression

  2021cites this paper
• ELTD1 as a multi-focal target for malignant gliomas: preclinical studies

  2021cites this paper
• A tale of two multi‐focal therapies for glioblastoma: An antibody targeting ELTD1 and nitrone‐based OKN‐007

  2021cites this paper
• Therapeutic targeting of membrane-associated proteins in central nervous system tumors.

  2021cites this paper
• ELTD1 as a biomarker for multiple sclerosis: Pre-clinical molecular-targeted studies in a mouse experimental autoimmune encephalomyelitis model.

  2021cites this paper
• Adhesion GPCRs in Glioblastoma

  2021cites this paper
• Adhesion G protein-coupled receptors in glioblastoma

  2021cites this paper
• ELTD1—An Emerging Silent Actor in Cancer Drama Play

  2021cites this paper
• Pathophysiology of blood-brain barrier in brain tumor. Novel therapeutic advances using nanomedicine.

  2020cites this paper
• Assessment of an scFv Antibody Fragment Against ELTD1 in a G55 Glioblastoma Xenograft Model

  2020cites this paper
• Surfen‐mediated blockade of extratumoral chondroitin sulfate glycosaminoglycans inhibits glioblastoma invasion

  2019cites this paper
• Optimized monoclonal antibody treatment against ELTD1 for GBM in a G55 xenograft mouse model

  2019cites this paper